Table 10– Studies designed to assess responsiveness of the incremental shuttle walk test (ISWT) and endurance shuttle walk test (ESWT) to interventions of known efficacy
First author [ref.]Studied populationField tests
PopulationSubjects nMean age yearsFEV1Field test studiedMean field test distance or time at baselineMean change in walking distance or timeSRM
Dyer [206]Elderly with CAL507672% predISWT177.7 m13.2±4.8% (-28.5–61.3%)NA
Pepin [105]COPD176556% predESWT405 s164±177 s#0.93
Pepin [106]COPD GOLD stage II–III146450% predESWT420 m
253 s
144±219 m#0.66
6MWT553 m7±17 m0.42
Brouillard [107]COPD206552% predESWT373 s117±208 s#0.56
Sandland [219]Severe hypoxaemic COPD41710.85 LISWT192,4 m33.2±46.3 m#0.72
ESWT156.0 m112.0±217.1 m#0.52
Revill [233]COPD with exertional desaturation236733% predESWT273 s
221 m
91 (43–139) s#
66 (27–106) m#
NA
6MWT309 m6 (-6–19) mNA
Eaton [234]COPD20710.95 LESWT313 m302±387 m#0.78
6MWT351 m47±79 m#0.59
Leung [232]COPD GOLD stage I–IV, walking training group177156% predISWT402 m54±37 m1.46
ESWT397 s439±346 s1.27
COPD GOLD stage I–IV, cycling training group157253% predISWT373 m45±29 m1.55
ESWT375 s160±204 s0.78
  • Data are presented as mean±standard error of the measurement (95% CI), unless otherwise stated. FEV1: forced expiratory volume in 1 s; SRM: standardised response mean (mean change/sd of change); CAL: chronic airflow limitation; NA: not available and/or incalculable; COPD: chronic obstructive pulmonary disease; GOLD: Global Initiative for Chronic Obstructive Lung Disease; 6MWT: 6-min walk test. #: p<0.05; : p-value NA.